BNB Plus secures initial $4.1M to expand digital asset treasury and strategic review
What's the deal? BNB PlusDealroom has a profile for this one. Try Dealroom → Corp., a Nasdaq-listed company formerly known as Applied DNA SciencesDealroom has a profile for this one. Try Dealroom →, has secured $4.1 million in convertible preferred financing as it repositions itself around a digital asset treasury and blockchain infrastructure strategy. Total proceeds are expected to reach roughly $5 million.
The funds will go toward expanding digital asset holdings, supporting working capital, and financing a strategic review of the company's operations and capital structure. After the financing closes, BNB Plus expects to hold more than $16.4 million in cash and digital assets.
Investors include Comstock Multichain Fund, managed by Silvermine Capital Advisors, and Off the Chain, LP. As part of the deal, BNB Plus will engage GlobalStake Infrastructure — a Web3 company specialising in validator operations and staking — to lead a strategic review.
Why now? The pivot reflects renewed institutional appetite for tokenised finance, staking yield, and decentralised financial systems. BNB Plus is reorienting around the Binance ecosystem while keeping its LineaRx biotech subsidiary, which recently reached profitability in Q2 of fiscal 2026.
GlobalStake's review will evaluate two paths: expanding into digital asset and AI infrastructure, and potential monetisation of LineaRx through partnerships, licensing, asset sales, or other transactions.
What could go wrong? The company is still small, and pivoting from biotech to crypto treasury is a dramatic shift. The financing structure — two classes of convertible preferred stock with dividend and liquidation preferences — gives investors downside protection, but it also signals the risk inherent in this transition.
The Series B-1 preferred shares were priced at $1.05, well above the recent common stock trading price. BNB Plus can capitalise dividend obligations into principal for the first two years rather than paying cash, preserving liquidity but potentially diluting shareholders down the line.
The signal: BNB Plus's pivot from biotech to digital asset treasury mirrors a broader pattern of smaller Nasdaq-listed firms repurposing their public-market shells to offer investors regulated exposure to blockchain infrastructure and staking yield. The participation of dedicated digital asset investment funds such as Off the Chain CapitalDealroom has a profile for this one. Try Dealroom → and Silvermine Capital Advisors suggests this corporate treasury playbook is attracting increasingly specialised, institutional-grade backers rather than purely opportunistic capital.
Read more: citybiz.co
